2023-11-12T17:47:37-07:00 2023-06-30 990 2022-07-01 030485196 MYELIN REPAIR FOUNDATION INC MYEL 20111 Edinburgh Drive Saratoga CA 95070 Scott Johnson Chief Executive Officer 4087610201 2023-11-13 1 1 11 1 AAL2 X 2022 2023-04-26 12:10:37Z Scott Johnson 20111 Edinburgh Drive Saratoga CA 95070 552239 0 X myelinrepair.org X 2002 CA Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. Myelin Repair Foundation is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 4 3 1 0 0 0 262804 527737 0 0 914 24502 21709 0 285427 552239 327257 230000 0 0 137838 138719 0 0 26179 73855 94640 538950 463359 -253523 88880 1330627 1550183 493264 623940 837363 926243 Accelerating the development of new therapeutics to prevent or repair damage to myelin caused by Multiple Sclerosis. The MRF is helping to identify biomarkers of myelin repair for use in myelin repair drug development and clinical trials 0 0 420858 230000 558798 We only have one area of program services and that is scientific research to benefit Multiple Sclerosis (MS) patients. Currently our research is focused on experiments to identify biomarkers to indicate repair of myelin damaged by MS. Over the last year, we focused our research on extracellular vesicles(EVs) isolated from blood. We currently have 8 investigations underway spread across Europe and North America. We have encouraging preliminary data showing that we can clearly distinguish MS patient EV's from healthy controls and may be able to identify sub-types of MS. 0 0 0 420858 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 6 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 X 4 3 0 0 0 0 0 0 0 1 1 1 0 1 1 1 1 1 1 1 0 0 CA X Louise Savoie 4088885542 2198 Hillstone Dr San Jose CA 95138 Scott Johnson CEO 20 0 X X 120000 0 0 Andy Cates Director 1 0 X 0 0 0 Bobby Mehta Director 1 0 X 0 0 0 Jim Gidwitz Director 1 0 X 0 0 0 120000 0 0 1 0 0 0 0 0 0 0 0 0 527737 0 527737 0 24502 24502 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 552239 24502 0 0 X 60000 60000 0 0 170000 170000 120000 88800 9600 21600 9325 6900 746 1679 9394 6952 751 1691 4688 4688 80446 80446 6716 4970 537 1209 2790 2790 463359 420858 16322 26179 271165 111449 847220 1254746 212000 168000 242 15988 1330627 1550183 493264 623940 0 0 493264 623940 X 837363 926243 0 0 837363 926243 1330627 1550183 88880 0 0 0 0 0 X 0 0 0 X 287392 253579 478580 262804 527737 1810092 287392 253579 478580 262804 527737 1810092 367908 1442184 6926 11669 699 914 31061 51269 51048 21709 0 72757 1934118 0 0.74565 0.68393 X Schedule A, Part II, Line 10 2020-forgiveness of PPP loan 2019-refund of unused research funds RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 Europe (including Iceland and Greenland) 0 0 Program Services Extracellular vesicles offer a promising avenue for the discovery of biomarkers to help tackle multiple sclerosis progression. By analyzing the cargo of EVs, we hope to obtain valuable insights on neuroinflammation, neurodegeneration, and treatment response. The objective of this project is to develop an analytical pipeline to assess the cargo of EVs found in the serum and secreted by neurons, astrocytes and oligodendrocytes. This pipeline will then be used to identify a blood-derived signature of MS. 170000 0 0 170000 Europe (including Iceland and Greenland) Scientific Research 170000 cash progress payments 0 contractual amount 0 1 0 0 0 0 0 0 Schedule F, Part I, Line 2 Grants outside the United States are treated the same as grants within the United States with regular required reports and conversations with recipients 1 Columbia University PO Box 29789 General Post office New York NY 100879789 50000 0 contractual amount This study will test the diagnostic potential of extracellular vesicles (EVs) released by microglia. Microglia are resident immune cells in the central nervous system (CNS) which perform multiple functions including, immune response to local environment, communication with all CNS cells (neurons, astrocytes and oligodendrocytes) and phagocytic clearance of misfolded proteins and apoptotic or necrotic cells. EVs derived from microglia can play an important role as mediators of both pathological and reparative mechanisms in MS. Microglia are known to play key roles in both active inflammation and remyelination in MS Nanosomix Inc 4 Little Pond Laguna Niguel CA 92677 10000 contractual amount Nanosomix analyzed samples for MRF 1 1 Schedule I, Part I, Line 2 The Recipients are subject to the terms and conditions of the sponsored research agreement between them and the MRF. The researchers' work is reviewed by the MRF Scientific Director, the Executive Committee, and the MFR president. Form 990, Part VI, Section A, Line 9 These are the addresses for the board members. Andy's is a work addresses. 1. Andy Cates 429N. Main Street, suite 100 Memphis, TN 38103. 2 Jim Gidwitz 440 S LaSalle, suite 3100, Chicago, IL 60605-5020. 3. Bobby Mehta 159 E. Walton Street, Chicago, IL 60611. Form 990, Part VI, Section B, Line 11b Form 990, Part VI, Section B, Line 11b - Form 990 is reviewed by the CEO and once the CEO approves, it is then forwarded to the board members for their review prior to filing. Board members are encouraged to review and forward their questions, if any, to the CEO Form 990, Part VI, Section B, Line 12c Officers, directors, and key employees are covered. Any and all conflicts are reviewed by disinterested board members and, if needed, by legal counsel. Persons with a conflict of interest will be restricted from making any key decisions for MRF as they relate to the interest unless otherwise approved by the majority of the disinterested parties. Form 990, Part VI, Section B, Line 15 Compensation is determined by the board of directors Form 990, Part VI, Section C, Line 19 Financial Statements, governing documents and policies are available upon request for the same period of time set forth in Sec.6104(D) Form 990, Part IX, Line 11g General Consulting